2023-508322-10-00招募中2 期
A Double-Blind, Placebo-Controlled, Crossover Pilot Study of the Efficacy and Safety of Fluasterone Buccal Tablet in the Control of Hyperglycemia in Adults with Endogenous Cushing’s Syndrome
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 24
- 试验地点
- 8
- 主要终点
- The primary efficacy endpoint is the change in area under the curve for glucose (AUCglucose) based on the 2-hour oGTT at week 12 versus baseline during each of the 12-week treatment periods.
研究概览
简要总结
To determine the effect of buccal fluasterone on hyperglycemia associated with the diagnosis of endogenous hypercortisolemia (possible Cushing’s syndrome) in patients suffering from impaired glucose tolerance or diabetes mellitus
研究设计
- 分配方式
- Randomized
- 主要目的
- Treatment Period 2
- 盲法
- Double (Carer, Subject, Investigator, Monitor)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 否
入选标准
- •Male or female patients aged 18 to 75 years, inclusive
- •Patient has read and signed the IRB/ Institutional Ethics Committee (IEC) approved ICF before screening procedures are undertaken
- •Has been evaluated within the previous 12 months for the possibility of endogenous Cushing syndrome (caused by either ACTH-dependent or ACTH-independent etiologies), meaning to fulfil 2 out of the 3 following criteria as per European guidelines: an elevated 24-hour urine free cortisol (UFC), above the upper limit of normal (ULN) as per the reference range of the laboratory assay, on two occasions, or an abnormal response to an overnight 1-mg dexamethasone suppression test (DST), i.e., an elevated blood cortisol over 1.8 µg/dL (50 nmol/L) measured between 8 AM and 9 AM, after a 1-mg dexamethasone oral administration between 11 PM and 12 PM the previous night, or an abnormal midnight serum or salivary cortisol levels prior to initiation of study treatment, meaning: for “sleeping” midnight serum cortisol to be greater than 1.8 μg/dl (>50 nmol/liter), OR for “awake” midnight serum cortisol to be greater than 7.5 μg/dl (>207 nmol/liter), or for late-night salivary cortisol (LNSC) to be above the ULN as per the reference range of the laboratory assay
- •Has been diagnosed with impaired glucose tolerance (IGT), i.e., 2-hour plasma glucose ≥140 mg/dl and <200 mg/dl during an oGTT, or type 2 diabetes mellitus according to EASD/ADA guidelines, with HbA1c <9% during the last three months
- •If the patient receives treatment(s) for hyperglycemia, the dose(s) must have been stable for the 60 days prior to the Pre-Screening Visit.
- •If the patient has received post-operative glucocorticoid replacement therapy following surgery for Cushing’s Disease, he/ she must have discontinued such therapy for at least one week, or 5 half-lives, whichever is longer, prior to Screening Visit #1.
排除标准
- •Has an acute or unstable medical condition
- •Has history of currently active malignancy involving any organ system (other than localized basal cell carcinoma of the skin and adrenal carcinoma)
- •Has electrocardiogram (ECG) at Screening Visit #1 that shows prolongation of QTcF interval >450 msec in males or >470 msec in females, or any clinically significant dysrhythmia
- •Has a history of congestive heart failure, unstable angina, sustained ventricular tachycardia, clinically significant bradycardia, advanced heart block, or acute myocardial infarction within 12 months of Screening Visit #1
- •Has a history of alcohol or drug abuse within 6 months prior to Screening Visit #1
- •Has 2-hour plasma glucose <140 mg/dl in oGTT at Screening Visit #1
- •Has HbA1c >9% within the last 3 months
- •Has uncontrolled hypertension defined as >170/110 mmHg
- •Has uncontrolled hypothyroidism or hyperthyroidism
- •Has received treatment with mifepristone within the 2 months period prior to Screening Visit #1
- •Is receiving other medicinal products interfering with cortisol production and/or metabolism
- •Is a pregnant woman or woman of childbearing potential (WOCBP) who is receiving oral contraceptive pills or is unable or unwilling to utilize appropriate methods of contraception during the study
- •Has clinical laboratory results for hematology at Screening Visit #1 that includes one or more of the following: hemoglobin <9 g/dL, total WBC <3000 cells/mm3, ANC <1500 cells/mm3, platelet count <100K /mm3
- •Has clinical laboratory results for chemistry at Screening Visit #1 that includes one or more of the following: ALT >5 x ULN, AST >5 x ULN, bilirubin >2 x ULN, estimated creatinine clearance <50 mL/min (by Cockroft-Gault equation)
- •Has hypokalemia (serum potassium < 3.0 mg/dL) at Screening Visit #1
- •Has positive urine drug screen for drugs of abuse, excepting prescribed medications
- •Is a patient who, in the opinion of the Investigator, is not able to comply with study requirements
- •Has G6PD deficiency
- •Is a male subject with female partner of childbearing potential, who is unwilling to use a condom and his partner to use an additional form of adequate contraception
- •Is a female who is breast feeding
- •Has received treatment with an investigational product (drug, biologic agent, and/or device) within 30 days or 5 half-lives, whichever is longer at the time of Screening Visit #1
- •Has received pituitary radiation (stereotactic radiosurgery) within 2 years of Screening Visit #1 or conventional radiation within 3 years of Screening Visit #1
- •Has a history of an allergic reaction to fluasterone or DHEA
- •Has a non-endogenous source of hypercortisolism such as factitious hypercortisolemia (exogenous source of glucocorticoid, iatrogenic Cushing’s syndrome), factitious or therapeutic use of ACTH
- •Has pseudo-Cushing’s syndrome
结局指标
主要结局
The primary efficacy endpoint is the change in area under the curve for glucose (AUCglucose) based on the 2-hour oGTT at week 12 versus baseline during each of the 12-week treatment periods.
The primary efficacy endpoint is the change in area under the curve for glucose (AUCglucose) based on the 2-hour oGTT at week 12 versus baseline during each of the 12-week treatment periods.
次要结局
- The change in AUCglucose based on the 2-hour oGTT at week 6 versus baseline during each of the 12-week treatment periods.
- The change in HbA1c at weeks 6 and 12 versus baseline during each of the 12-week treatment periods
- The change in serum lipid profiles at weeks 6 and 12 versus baseline during each of the 12-week treatment periods
- The change in body habitus as evaluated by DEXA scanning at weeks 6 and 12 versus baseline during each of the 12-week treatment periods
- The change in hepatic steatosis/fibrosis as evaluated by TEand MRI-PDFF at week 12 versus baseline during each of the 12-week treatment periods.
研究者
Medical Director
Scientific
Sterotherapeutics LLC
研究点 (8)
Loading locations...
相似试验
尚未招募
不适用
CGM-Based Glycemic Analysis After ESISpinal StenosisHyperglycemiaIntervertebral Disc HerniationNCT07280780Korea University Anam Hospital36
已完成
1 期
Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy SubjectsNCT07275775InventisBio Co., Ltd100
招募中
4 期
Evaluation of efficacy and tolerance of fludrocortisone (Flucortac) in the treatment of neurogenic orthostatic hypotension2024-517841-16-00H.A.C. Pharma90
招募中
4 期
Using a Steroid Mouthwash to Prevent Mouth Sores During ChemotherapyNCT07287826Woman's45
招募中
1 期
A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune DiseasesNCT07275736Juventas Cell Therapy Ltd.18